High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone.

Abstract

The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. We retrospectively reviewed 55 patients with newly diagnosed PTCL treated with CHOP from August 1999 to May 2009 at our institution. We analyzed six laboratory parameters, including thymidine kinase (TK) activity, to evaluate overall survival, which was the primary end-point. In multivariate analysis, the overall survival was significantly worse in patients with high TK activity (hazard ratio 34.8, 95% confidence interval [CI] 1.03-1176.23). The overall response rate among patients with high TK activity was 21.4%, significantly poorer compared with other parameters (p = 0.001). High TK activity predicts poor overall survival among patients with newly diagnosed PTCL treated with CHOP. Response to CHOP treatment is significantly decreased in patients with PTCL with high TK activity.

• Authors: Kazuhito Suzuki, Yasuhito Terui, Kenji Nakano, Eriko Nara, Kentaro Nasu, Kyoko Ueda, Noriko Nishimura, Yuko Mishima, Sakura Sakajiri, Masahiro Yokoyama, Shunji Takahashi, Kiyohiko Hatake
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 53 Issue 5 Pg. 849-54 (May 2012) ISSN: 1029-2403 [Electronic] United States
• PMID: 22035416 (Publication Type: Journal Article)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Thymidine Kinase
• Prednisone

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide
• Doxorubicin
• Humans
• Lymphoma, T-Cell, Peripheral (diagnosis, drug therapy, mortality)
• Predictive Value of Tests
• Prednisone
• Prognosis
• Retrospective Studies
• Survival Rate
• Thymidine Kinase (metabolism)
• Vincristine